Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
SponsorBrigham and Women's Hospital
Primary outcomeTime to all-cause mortality (overall survival)
Advanced Breast Cancer
Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS
SponsorReproductive & Genetic Hospital of CITIC-Xiangya
Primary outcomeLive birth rate
PCOS
The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)
SponsorInternational Peace Maternity and Child Health Hospital
Primary outcomeLive birth
LetrozoleInfertility, Female
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
Primary outcomeReal-World Progression Free Survival (rwPFS): Using Kaplan-Meier Method
Metastatic Breast Cancer
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Primary outcomeOverall Survival (OS)
Metastatic Breast Cancer
SponsorIndira IVF Hospital Pvt Ltd
Primary outcomeOngoing pregnancy rate
Adenomyosis
The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Primary outcomeongoing pregnancy rate
Infertility
Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine
SponsorHeilongjiang University of Chinese Medicine
Primary outcomeLive-birth rate
Polycystic Ovary Syndrome
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
SponsorChinese Academy of Medical Sciences
Primary outcomeRatio of patients whose low density lipoprotein-cholesterol（LDL-C） level ≥ 4.14 mmol/L in 2 years of administration among groups
Breast Cancer
Letrozole Plus Misoprostol Versus Misoprostol Only in Induction of Missed Abortion
Primary outcomeIncidence of bleeding
LetrozoleMisoprostolInductionMissed Abortion
Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.
SponsorMansoura University
Primary outcomeoccurrence of ovulation and midcycle endometrial thickness (mm).
Polycystic Ovary Syndrome
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
SponsorThe Affiliated Hospital of Qingdao University
Primary outcomeProgression-free survival(PFS)
Breast CancerNeoplasmsBreast Diseases
Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients
SponsorCapital Medical University
Primary outcomeProgression free survival(PFS) of the subjects
Breast NeoplasmsNeoplasm Metastasis
Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle
SponsorMenoufia University
Primary outcomelive birth rate
Ovarian Stimulation
Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve
SponsorSheba Medical Center
Primary outcomeClinical pregnancy rates
Infertility
Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy
SponsorThe University of Hong Kong
Primary outcomeRecurrence of endometrioma
Endometriotic Cyst of Ovary
the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women
SponsorLaylay Mohammed Khalleefah Alhibshi
Primary outcomethe endometrial thickness
Endometrial ThicknessPregnancy Rate
Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients
SponsorAl-Azhar University
Primary outcomeComparison of baseline FSH level between letrozole-sensitive and letrozole-resistant PCOS patients.
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Efficacy of Letrozole and CC Alone in an IUI Program in Cases With Surgically Treated Minimal to Mild Endometriosis
SponsorMansoura University
Primary outcomeClinical pregnancy rate per cycle
Endometriosis
Only Gonadotropin Vs. Letrozole Combined Gonadotropin Stimulation in IUI Cycles
Primary outcomeClinical Pregnancy Rate
Infertility Unexplained
Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS
Primary outcomeNumber of participants with successful ovulation
Polycystic Ovarian Syndrome (PCOS)
FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles
SponsorUniversity of Novi Sad
Primary outcomeClinical Pregnancy Rate
Infertility FemaleFrozen Embryo Transfer (FET)
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
Primary outcomedetermine efficacy of the aromatase inhibitor and Gnrh antagonist to achievement of resolution of ectopic pregnancy determined by serum hCG levels below laboratory immunoassay detection <15 IU/l.Results will be statistically analyzed,then evaluated .
Ectopic Pregnancy
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Primary outcomeKnee Cartilage Volume
Arthralgia
Intrauterine Insemination With Letrozole Versus in Natural Cycle
SponsorPeking University Third Hospital
Primary outcomeongoing pregnancy
InfertilityIntrauterine Insemination
Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
SponsorMst.Sumyara Khatun
Primary outcomeOvulation Rate
PCOS
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
Primary outcomeMiscarriage Achievement
Miscarriage
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
SponsorQueen Savang Vadhana Memorial Hospital, Thailand
Primary outcomeRate of complete abortion
Medical; Abortion, Fetus
Reproductive Hormonal Alterations in Obesity
SponsorUniversity of Colorado, Denver
Primary outcomeChanges in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1)
Obesity
Magnesium Oxide and Letrozole Versus Letrozole Alone on Ovarian Response in Insulin Resistant PCOS
SponsorBangladesh Medical University
Primary outcomeOvulation rate
Insulin Resistant PCOS
Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy
SponsorYuzuncu Yil University
Primary outcomeDecrease in β-hCG levels
Ectopic Pregnancy
Letrozole as a Treatment of Endometrial Cancer
SponsorUniversity of California, Davis
Primary outcomeChanges in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
Endometrial Carcinoma
Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women
SponsorUniversity of Saskatchewan
Primary outcomeTo evaluate differences in the mechanisms of atresia, initiation of a new synchronous follicular wave, interval to follicle wave emergence, interval to emergence of dominant follicle, interval to menstruation, and endometrial thickness/pattern.
Ovarian Follicle
Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure
SponsorUniversiti Kebangsaan Malaysia Medical Centre
Primary outcomeendometrial abv3-integrin expression expressions
Miscarriage, Recurrent
A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
SponsorSecond Affiliated Hospital of Soochow University
Primary outcomeProgression Free Survival
Breast Neoplasms
Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers
Primary outcomeChange in Proliferative response
Breast Cancer
Letrozole add-on in the Treatment of Cesarean Scar Pregnancy
SponsorJagiellonian University
Primary outcomeBlood loss during the procedure expressed as a decrease in hemoglobin concentration
Cesarean Scar Pregnancy
Bioequivalence Study of Letrozole 2.5 mg Tablets
Primary outcomeLetrozole : AUC0-tz
Healthy
Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)
SponsorGABRIEL MONTEIRO PINHEIRO
Primary outcomeOvulation rate
PCOS (Polycystic Ovary Syndrome)InfertilityAnovulation
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
SponsorDartmouth-Hitchcock Medical Center
Primary outcomeChange in Insulin Receptor Substrate 1 (IRS-1) / Phosphoinositide 3-kinase (PI3K) / Serine-threonine Protein Kinase (AKT) Pathway Activation
Breast Cancer
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
SponsorUniversity of Virginia
Breast CancerOsteoporosis
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
SponsorInstitut Claudius Regaud
Primary outcomeCorrelation between pharmacokinetic and pharmacogenetic parameters
Hormono-depending Adjuvant Breast Cancer
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
SponsorPalleos Healthcare GmbH
Breast Neoplasm
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeNumber of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.
Breast Cancer
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
Primary outcomeNumber of Participants With Treatment-Emergent Adverse Events (All Causalities)
Breast Cancer
The Outcomes of ICSI Cycles With and Without Letrozole
SponsorMansoura University
Primary outcomeongoing pregnancy rate.
EMBRYO IMPLANTATION
Letrozole Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion
Primary outcomecomplete abortion rate
Missed Abortion
Follicular Synchronization in PCOS Patients Undergoing ICSI
SponsorMansoura University Hospital
Primary outcomethe number of asynchronized follicles in both groups
Polycystic Ovarian Syndrome
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
Polycystic Ovary SyndromePCOSInfertility
Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial
SponsorUniversity of Palermo
Primary outcomeOngoing pregnancy rate
Adenomyosis of UterusInfertility Assisted Reproductive Technology
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
SponsorKK Women's and Children's Hospital
Primary outcomeRate of complete abortion by Day 21-28
Abortion in First Trimester
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
SponsorGBG Forschungs GmbH
Primary outcomeTime-to-treatment failure (TTF)
Metastatic Breast Cancer
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
SponsorNovartis Pharmaceuticals
Primary outcomeSafety and tolerability of Letrozole
Locally Advanced Breast Cancer
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeTime to progression as assessed by clinical palpation and radiologic imaging every 3 months
Metastatic Breast Cancer
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
SponsorUniversity of Washington
Primary outcomeChanges in Ki67
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Breast AdenocarcinomaInvasive Breast Carcinoma of No Special Type
Dosage Optimization for Letrozole Treatment
SponsorBushehr University of Medical Science
Primary outcomenormal follicular size
Infertility
Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women
SponsorUniversity of Saskatchewan
Primary outcomefate of the dominant follicle or luteal structure
Fertility
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
SponsorInstitut Claudius Regaud
Primary outcomeRates of patients for which specific tissular miRNAs are detected in blood before treatment (D0)
Breast Cancer
Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men
SponsorUniversity Hospital, Ghent
Primary outcomecardiac function parameters
Obesity
Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions
SponsorMansoura University
Primary outcomeOperative time
Myoma;Uterus
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
SponsorWake Forest University Health Sciences
Primary outcomeNumber of Participants With Progesterone Level Greater Than 1.5 ng/mL
Ovulation DisorderOvarian Cysts
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
SponsorRigshospitalet, Denmark
Primary outcomeChange in plasma total testosterone concentration after 24 weeks from baseline
HypogonadismHypogonadism, MaleHypogonadotropic Hypogonadism
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
SponsorETOP IBCSG Partners Foundation
Primary outcomeDisease-free Survival (DFS)
Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Primary outcomeInvasive breast cancer-free survival (IBCFS)
Breast Cancer, Early Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
SponsorNSABP Foundation Inc
Primary outcomeDisease-free Survival
Breast Cancer
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
SponsorSWOG Cancer Research Network
Primary outcomeInvasive Disease-Free Survival (IDFS)
Breast Cancer
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Primary outcome5-years Invasive disease free survival
Breast CancerAdjuvant Therapy
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
SponsorNational Cancer Institute, Naples
Primary outcomedisease free survival in premenopausal patients
Breast Cancer
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeNumber of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator
Breast Neoplasms
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Primary outcomeProgression Free Survival (PFS)
Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
SponsorNovartis Pharmaceuticals
Primary outcomePercentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.
Bone LossBreast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Primary outcomeProgression Free Survival (PFS) by BICR
Breast Cancer
ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer
SponsorAzienda Ospedaliero-Universitaria Careggi
Primary outcomePatient reported outcome measures (PROM) HRQoL as assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30
Breast Cancer
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Primary outcomeProgression-Free Survival (Arm 1 vs arm 2)
Advanced Breast Cancer
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
SponsorAlliance for Clinical Trials in Oncology
Primary outcomeAverage intra-patient change in total lumbar spine (L1-L4) bone mineral density (BMD) as measured by dual energy x-ray absorptiometry at baseline and 1 year after completion of study treatment
Breast CancerOsteoporosis
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
SponsorEli Lilly and Company
Primary outcomeProgression Free Survival (PFS)
Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
SponsorEli Lilly and Company
Primary outcomeProgression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)
Breast Cancer
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary outcomeProgression-free survival (PFS)
Low Grade Fallopian Tube Serous AdenocarcinomaOvarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
SponsorAhon Pharmaceutical Co., Ltd.
Primary outcomePFS is determined by IRC
Advanced Breast CancerFemale Breast Cancer
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
SponsorShengjing Hospital
Primary outcomeProgression-free survival
Breast Cancer
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
Primary outcomeDisease free survival
Breast Cancer
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
SponsorGruppo Italiano Mammella (GIM)
Primary outcomeProgression-free survival
Breast Cancer
The Clinical Trial of Acupuncture Pre-treatment on PCOS
SponsorThe First Affiliated Hospital of Guangzhou Medical University
Primary outcomeLive birth rate
Polycystic Ovary Syndrome
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
SponsorSpanish Breast Cancer Research Group
Primary outcomeProgression-free Survival (PFS)
Breast Cancer
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
SponsorUniversity of Virginia
Primary outcomeProportion of participants who omit Radiation Therapy (RT) and are non-adherent to Endocrine Therapy (ET)
Breast Cancer Female
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
SponsorRovi Pharmaceuticals Laboratories
Primary outcomeProgression Free Survival (PFS)
Advanced, Metastatic Breast Cancer
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
SponsorNovartis Pharmaceuticals
Primary outcomeProgression-Free Survival (PFS) by Cycle 1 Day 15 Complete Mutational Dynamic Change
Breast Cancer
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Primary outcomeProgression Free Survival (PFS) per blinded independent central review (BICR)
Low Grade Serous Ovarian Cancer
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomePercent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Primary outcomeThe occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Breast Cancer
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Primary outcomeobjective response rate (ORR)
Breast Cancer Female
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
Primary outcomeProgression-free survival (PFS)
Cancer Metastatic
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Primary outcomeChanges in Ki67 and PCNA after 4 months of treatment with letrozole vs tamoxifen citrate
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
Primary outcomeSurvival without contralateral or unilateral invasive breast cancer at 5 years (prior breast cancer)
brca1 Mutation Carrierbrca2 Mutation CarrierBreast CancerHereditary Breast/Ovarian Cancer (brca1, brca2)
Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.
Primary outcomeTo determine ovarian volume in millilitres in oocyte donors according to whether or not they receive the treatment during the luteal phase after ovarian stimulation.
Luteinised Follicular Cyst
Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females
SponsorAin Shams University
Primary outcomeThe primary outcome is cumulative ovulation rate
Polycystic Ovary SyndromeInfertility, Female
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
SponsorEnte Ospedaliero Ospedali Galliera
Primary outcomeProgression-free survival (PFS)
Carcinoma, Ovarian EpithelialLow Grade Serous Adenocarcinoma of Ovary
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
SponsorZhejiang Cancer Hospital
Primary outcomeeffective rate
Neoadjuvant Therapy
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole
SponsorBeni-Suef University
Primary outcomeovulation rate
Polycystic Ovary Syndrome
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
SponsorBeni-Suef University
Polycystic Ovary Syndrome
Efficacy of Letrozole in Recurrent Ovarian Cancer
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary outcomeProportion of patient alive at 12 months
Epithelial Ovarian Cancer
Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome
SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Primary outcomeThe number of participants having mature follicle (mean diameter ≥18mm)
Polycystic Ovarian Syndrome (PCOS)Infertility
Short-term Effects of Aromatase Inhibition in Obese Men
SponsorRijnstate Hospital
Primary outcomeBody weight
Hypogonadotrophic HypogonadismObesity
Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.
SponsorKK Women's and Children's Hospital
Primary outcomeSperm density
Azoospermia, NonobstructiveOligozoospermia
Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion
SponsorAin Shams University
Primary outcomeDuration of induction of abortion
Miscarriage
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Primary outcomeThe complete response rate (CRR) at 32 weeks after initiating treatment.
Endometrial CancerFertility
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
Primary outcomepathological complete remission rate
Tubular Breast CancerMucinous Breast CancerInvasive Ductal Breast CancerInflammatory Breast Cancer
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
SponsorZagazig University
Primary outcome(β-hCG) level
Gestational Trophoblastic Disease
Comparative Evaluation of the Efficacy of Letrozole, L-Carnitine, and Their Combination on Sperm Quality, Oxidative Stress, and ART Outcomes in Men With Idiopathic Oligoasthenoteratozoospermia.
SponsorTehran University of Medical Sciences
Primary outcomeSperm concentration (×10⁶/mL) after 3 months of treatment
Idiopathic OligoasthenoteratozoospermiaMale Infertility
Vitamin D and Calcium Supplementation in Breast Cancer
Primary outcomeOsteocalcin level
Breast Cancer
Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment
SponsorHelsinki University Central Hospital
Primary outcometesticular volume
Constitutional Delay of Growth and Puberty
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
SponsorGeorgetown University
Primary outcomeNumber of Patients Who Complete Planned Oncologic Therapy Without the Development of a Hematological Event
Hormone Receptor Positive HER-2 Negative Breast Cancer
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Primary outcomeComplete response rates within 28 weeks of treatment
Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone ResistanceObesity
Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
Primary outcomeObjective response rate (complete remission, partial remission,no change, progressive disease) by clinical palpation and radiologic imaging every 3 months until disease progression
Metastatic Breast Cancer
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Primary outcomethe 3-year Progression-Free-Survival(PFS)
Endometrial Cancer
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
SponsorGreater Baltimore Medical Center
Primary outcomeSingle Arm Trial With Combination of Everolimus and Letrozole in Treatment With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation; Tumor Response to treatment with Everolimus and Letrozole using RECIST Criteria
Uterine Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
SponsorQuantumLeap Healthcare Collaborative
Primary outcomeDetermine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.
Breast NeoplasmsBreast CancerBreast TumorsAngiosarcomaTNBC - Triple-Negative Breast CancerHER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorHormone Receptor Negative TumorEarly-stage Breast CancerLocally Advanced Breast Cancer
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
SponsorFujian Cancer Hospital
Primary outcome3-year invasive disease-free survival
Breast DiseasesBreast NeoplasmsDalpiciclibEndocrine Breast DiseasesCDK4/6 InhibitorHR+/HER2- Breast Cancer
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
Primary outcome1-year Progression Free Survival
Metastatic Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
SponsorNovartis Pharmaceuticals
Primary outcomeCore Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months
Breast Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Primary outcomeNumber of participants with dose-limiting toxicities in the Dose Escalation Arms.
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
SponsorNSABP Foundation Inc
Primary outcomeMeasurement of the Proliferation Marker Ki67 (% Positive Tumor Cells)
Breast CancerBreast CarcinomaBreast Tumors
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
SponsorMerck Sharp & Dohme LLC
Primary outcomeProgression-Free Survival (PFS) - All Cohorts
Malignant Neoplasm
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
Primary outcomeProgression-Free Survival (PFS) Assessed by Investigator
Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast CancerHR+/HER2+ Breast Cancer
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
SponsorShengjing Hospital
Primary outcomePathologic Complete Response Rate (tpCR: ypT0-is/ypN0)
Breast Cancer
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeProgression-free Survival
Breast Cancer
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
Primary outcome6 months Progression free survival rate
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.
SponsorSt Vincent's Hospital
Primary outcomeGeometric mean suppression of proliferation marker Ki67
Early-stage Breast CancerHormone Receptor Positive Tumor
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Primary outcomeRecurrence Free Survival (RFS)
Locoregional RecurrenceHormone Receptor-positive Breast CancerHER2-negative Breast Cancer
A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer
SponsorCambridge University Hospitals NHS Foundation Trust
Primary outcomeDetermination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment (%) at baseline compared to Day 15 (+ ≤4 days).
Breast Cancer
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Primary outcomeClinical response at 24 weeks
Breast Cancer
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Primary outcomeProgression Free Survival (PFS)
Breast Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Primary outcomeConfirmed Objective Response Rate (ORR)
Ovarian Cancer
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
SponsorJapan Breast Cancer Research Group
Primary outcomeTime to failure of strategy (TFS)
Metastatic Breast Cancer
Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Primary outcomeSub-cutaneous late toxicity
Breast Cancer
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
SponsorAsan Medical Center
Primary outcomeProgression free survival (PFS)
Metastatic Breast Cancer
Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET
Primary outcomeClinical pregnancy rate per started cycle
Infertility
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Primary outcomeThe incidence of grade ≥3 neutropenia at the end of cycle 1 (each cycle is 28 days)
Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
SponsorLund University Hospital
Primary outcomeClinical benefit rate.
Breast Cancer
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
SponsorCancer Care Hospital & Research Centre Foundation, Lahore
Primary outcomeExtent of Axillary Nodal Pathologic Complete Response (pCR)
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
SponsorSeoul National University Hospital
Primary outcomeConversion Rate
Breast Cancer
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
Primary outcomeRate of PEPI Score 0 at Surgery Between Ribociclib Containing Arms (Combined) vs. Letrozole Alone Arm.
Breast Cancer
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Primary outcomePercentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14
Breast Cancer
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
SponsorSOLTI Breast Cancer Research Group
Primary outcomeRate of pCRBL (ypT0/is ypN0) at surgery
Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
SponsorBristol-Myers Squibb
Primary outcomeNumber of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population
Metastatic Breast Cancer
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Primary outcomeProgression - Free Survival (PFS)
HR Positive HER2 Negative Advanced Breast Cancer
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
SponsorNational Cancer Center, Korea
Primary outcomepathologic complete remission (pCR)
Breast CancerInvasive Breast Cancer
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
SponsorAlliance for Clinical Trials in Oncology
Primary outcomeMean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3)
Breast Cancer
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Primary outcomeComplete response rates within 16 weeks of treatment
Endometrial Neoplasm Malignant Stage I
Combined Immunotherapies in Metastatic ER+ Breast Cancer
SponsorWeill Medical College of Cornell University
Primary outcomeProgression free survival (PFS) will be measured
Breast Cancer
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
SponsorUniversity of Washington
Primary outcomeNumber of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness
ArthralgiaMusculoskeletal ComplicationsPainRecurrent Breast CancerStage I Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
A Study of Lerociclib in Participants With Advanced Breast Cancer
Primary outcomeIncidence of AEs and SAEs
Advanced Breast Cancer
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Primary outcome1. The proportion of (PEPI score 0 + pCR) in patients with discordant EPclin scores and Ki67 assessments who were randomly assigned to the "+CDK4/6i" group
Breast CancerEarly-stage Breast Cancer
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
SponsorEli Lilly and Company
Primary outcomeProgression-Free Survival (PFS)
Metastatic Breast Cancer
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
SponsorAlliance for Clinical Trials in Oncology
Primary outcomeIncidence of Adverse Events
Estrogen Receptor-positive Breast CancerHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
SponsorDana-Farber Cancer Institute
Primary outcomeComposite Endpoint: Number of Participants With Abemaciclib Discontinuation for Any Reason, Abemaciclib Dose Reductions, or the Inability of Study Participants to Reach the Target Dose of Abemaciclib (Full Dose 150 mg BID) at 3 Months (12 Weeks)
Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
SponsorHunan Cancer Hospital
Primary outcomeClinical Benefit rate (CBR)
Metastatic Breast Cancer
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
SponsorUniversity Hospital, Akershus
Primary outcomeTo study the change in levels of direct and indirect immunologic biomarkers of targeted cancer therapy with letrozole and ribociclib given in combination for patients with locally-advanced, ER-positive, HER-2 negative, luminal A7B breast cancer
Breast CancerHER2-negative Breast CancerER-positive Breast CancerLocally Advanced Breast CancerLuminal A Breast CancerLuminal B Breast Cancer
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Primary outcomeObjective Response Rate (ORR)
HR+/HER2- Advanced/Metastatic Breast Cancer
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
SponsorUniversity of Alabama at Birmingham
Primary outcomeThe Percentage of Participants With Pathologic Complete Response
Breast CancerCancer of the BreastBreast Neoplasm
Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram
SponsorAl-Mustansiriyah University
Primary outcomeThe seminal fluid analysis
Male Reproductive ProblemInfertility, Male
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Primary outcomeFrequency of Response
Advanced, Persistent, or Recurrent Endometrial Cancer
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
SponsorUniversity of Chicago
Primary outcomePathological Complete Response
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHER2-positive Breast CancerBreast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
SponsorHenan Cancer Hospital
Primary outcomepathologic complete response
Breast CancerHER2-positive Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
SponsorNational Cancer Centre, Singapore
Primary outcomeClinical benefit response rate (complete response, partial response, or stable disease for > 24 weeks)
Breast Cancer
Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin
SponsorAhon Pharmaceutical Co., Ltd.
Primary outcomeOverall response rate
Breast Neoplasms
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
Primary outcomeDifference on Recurrence Score between pre and post-treatment (molecular results)
Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Primary outcomeNumber of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Ductal Carcinoma in SituEstrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerStage I Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
SponsorM.D. Anderson Cancer Center
Primary outcomeClinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.
Endometrial Cancer
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Primary outcomeNumber of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1
NeoplasmsBreast Neoplasms
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Primary outcomePercentage of Participants with Adverse Events (AEs)
Breast Cancer
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
SponsorUniversity of Washington
Primary outcomeResponse to abemaciclib + endocrine therapy
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast CarcinomaLocally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
SponsorM.D. Anderson Cancer Center
Primary outcomeObjective Response Rate (ORR)
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveKIT PositivePDGFR PositivePostmenopausalProgesterone Receptor PositivePrognostic Stage IV Breast Cancer AJCC v8
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Primary outcomeChange in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months
Breast Cancer
Abemaciclib and Letrozole to Treat Endometrial Cancer
SponsorGynecologic Oncology Group
Primary outcomeProgression-free survival
Endometrial Cancer
Ribociclib and Letrozole Treatment in Ovarian Cancer
SponsorGynecologic Oncology Group
Primary outcomeObjective Response Rate (ORR)
Low Grade Serous Carcinoma
TRial on the Endocrine Activity of Neoadjuvant Degarelix
SponsorETOP IBCSG Partners Foundation
Primary outcomeTime to Optimal Ovarian Function Suppression
Breast Cancer Invasive Nos
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
SponsorVanderbilt-Ingram Cancer Center
Primary outcomeNumber of Patients With Pathological Complete Response.
Breast Cancer
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
SponsorTranslational Research in Oncology
Primary outcomeProgression Free Survival (PFS)
Breast Neoplasms
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
SponsorUniversity of California, San Francisco
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
Primary outcomeChange in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration.
Breast Cancer
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
SponsorNational Cancer Centre, Singapore
Primary outcomeObjective Response Rate (ORR) per RECIST version 1.1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Letrozole in Uterine Leiomyosarcoma
Primary outcomeProgression Free Survival
Uterine Leiomyosarcoma
Letrozole in the Treatment of Severe and Recurrent Endometriosis
SponsorNovartis Pharmaceuticals
Primary outcomeResponse rates (CR, PR, NC, PD) during treatment of advanced endometrial cancer assessed by tumor marker assessments and radiologic imaging at week 12 then q 12 weeks x 1 year then q 16 weeks
Severe and Recurrent Endometriosis
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Primary outcomeFeasibility of the trial
Breast Cancer
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
SponsorMedical College of Wisconsin
Primary outcomeChange in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy.
Breast CancerInvasive Breast Cancer
A Study of Letrozole in the Treatment of Endometrial Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeResponse rates (complete response, partial response, no change, progressive disease) measured by tumor marker assessments and radiologic imaging at week 12 then every 12 weeks x 1 year followed by every 16 weeks
Recurrent and Metastatic Endometrial Cancer
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
SponsorShengjing Hospital
Primary outcomeBreast Pathological Complete Response Rate (bpCR)
Breast CancerHR Positive, HER2 Positive Breast Cancer
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
Primary outcomeTo determine the proportion of patients with ER and/or PR positive, ErbB2 positive tamoxifen resistant metastatic breast cancer who achieve complete remission (CR)
Metastatic Breast Cancer
ALPINE: Maintenance Letrozole/Abemaciclib
SponsorDana-Farber Cancer Institute
Primary outcomeMedian Progression Free Survival (PFS)
Endometrial CancerRecurrent Endometrial CancerTP53
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
SponsorYantai Yuhuangding Hospital
Primary outcomepathologic complete response
Breast Cancer
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Platinum-resistant Recurrent Ovarian Cancer
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
SponsorUniversity of Alabama at Birmingham
Primary outcomeThe primary objective is to estimate the pathological complete response rate of neoadjuvant therapy in operable newly diagnosed ER+ breast cancer patients using the combination of Avastin and Letrozole.
Breast Cancer
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
SponsorWashington University School of Medicine
Primary outcomeNumber of Participants With Pathologic Complete Response (pCR)
Breast CancerCancer of BreastBreast Carcinoma
RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
Primary outcomeLength of luteal phase (days from aspiration untill bleeding)
IVF
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
SponsorM.D. Anderson Cancer Center
Primary outcomeTo determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR
Breast CancerHER2-positive
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
SponsorSinai Hospital of Baltimore
Primary outcomeTumor Response to treatment with Everolimus and Letrozole using RECIST Criteria
Ovarian CancerEndometrial Cancer
Letrozole for Lymphangioleiomyomatosis
SponsorUniversity of Cincinnati
Primary outcomeRate of Change in Forced Expiratory Volume in 1 Second in ml/Month
Lymphangioleiomyomatosis
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
SponsorDana-Farber Cancer Institute
Primary outcomeTolerability at One Year of Ovarian Function Suppression (OFS) Using Leuprolide and Letrozole.
Breast Cancer
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeSafety during treatment
Postmenopausal Women With Advanced Breast Cancer
Letrozole in Patients With Ovarian Tumors
SponsorM.D. Anderson Cancer Center
Primary outcomeObjective Response Rate Following Treatment With Letrozole
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
SponsorNovartis Pharmaceuticals
Primary outcomeCell Cycle Response Rate Per Cell Proliferation Marker Ki67
Early Breast Cancer
Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer
SponsorSwiss Cancer Institute
Primary outcomeObjective response rate as assessed by CT scan or MRI every 3 months
Breast Cancer
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
SponsorShengjing Hospital
Primary outcomeTotal pathological complete response (tpCR)
Breast Cancer
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
SponsorUniversity of Maryland, Baltimore
Primary outcomeClinical Benefit Rate of Patients Treated With the Combination of Letrozole and Lapatinib and Then After Progression, Treated With Everolimus, Letrozole and Lapatinib.
Breast NeoplasmsEndocrine Breast DiseasesNeoplasm Metastasis
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
Primary outcomeObjective Tumor Response (Part 2)
Breast Cancer
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
SponsorM.D. Anderson Cancer Center
Primary outcomeProgression-free Survival (PFS)
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
SponsorWashington University School of Medicine
Primary outcomeAssess the effect of the combination of letrozole & PTK787/ZK222584 on disease progression.
Breast Neoplasms
Phase II Study of Everolimus Beyond Progression
Primary outcomeResponse Rate (Partial Response Plus Complete Response) Using RECIST
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Letrozole in Patients With Hepatopulmonary Syndrome
Primary outcomeAlveolar-Arterial Oxygen
Hepatopulmonary Syndrome
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
SponsorUniversity of Washington
Primary outcomeOverall response rate as measured by RECIST
Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Primary outcomeObjective Response Rate (ORR)
Metastatic Breast Cancer
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
SponsorEli Lilly and Company
Primary outcomeNumber of participants who experience at least 1 Dose Limiting Toxicity (DLT)
Breast CancerSolid Tumors, Adult
Study of AVZO-021 in Patients With Advanced Solid Tumors
SponsorAvenzo Therapeutics, Inc.
Primary outcomeOccurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)
Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCCNE1 AmplificationEpithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrial CancerTNBC - Triple-Negative Breast Cancer
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
SponsorSihuan Pharmaceutical Holdings Group Ltd.
Primary outcomeSingle agent and combination dose exploration study：AE evaluation
Metastasis Solid TumorsAdvanced Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeIncidence of Dose limiting toxicities (DLTs) - Phase lb only
Breast Cancer
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Primary outcomeDose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle
Breast CancerSolid Tumors
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
SponsorShandong Suncadia Medicine Co., Ltd.
Primary outcomeDose-limiting toxicity (DLT)
Advanced Unresectable or Metastatic Breast Cancer of Adults
Antagonist/Letrozole in Poor Responders
SponsorYazd Research & Clinical Center for Infertility
Primary outcomepregnancy rate
Ovarian Stimulation
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Primary outcomeProgression free survival
HER2-positive Breast CancerPostmenopausalMetastatic Breast Cancer
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
SponsorJiangsu HengRui Medicine Co., Ltd.
Primary outcomeDose-limiting toxicity (DLT)
Breast Cancer
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Primary outcomeSafety and tolerability of XL147 and letrozole and XL765 and letrozole
Breast Cancer
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
SponsorTraws Pharma, Inc.
Primary outcomeDose limiting toxicities (DLTs) will be tabulated and summarized by cohort
Endometrioid Endometrial Cancer
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
SponsorUniversity of Washington
Primary outcomeInsulin Sensitivity Quantified by Matsuda Index
Insulin ResistanceType 2 Diabetes MellitusObesityAndrogen DeficiencyMetabolic Disease
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
SponsorRutgers, The State University of New Jersey
Primary outcomeSorafenib in Combination With Fixed Dose of of 2.5mg of Letrozole Maximum Tolerated Dose (MTD)
Metastatic Breast Cancer
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
SponsorUniversity of Colorado, Denver
Primary outcomePhase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both
Breast Cancer
Letrozole Treatment in Normal and GnRH Deficient Women
SponsorMassachusetts General Hospital
Healthy Volunteers
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
SponsorHaihe Biopharma Co., Ltd.
Primary outcomeDose Limiting Toxicities (DLT)
Advanced Breast Cancer
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
SponsorEli Lilly and Company
Primary outcomeNumber of Participants with One or More Drug-Related Adverse Events
Breast Neoplasms
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
SponsorNovartis Pharmaceuticals
Primary outcomeIncidence and severity of dose-limiting toxicities (DLTs)
Advanced HR+/HER2- Breast Cancer
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Primary outcomeNumber of participants with dose limiting toxicities
Breast Cancer
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
SponsorBoehringer Ingelheim
Primary outcome[Cohort A, B, C & D] Maximum Tolerated Dose (MTD) of Xentuzumab
NeoplasmsBreast Neoplasms
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
SponsorRovi Pharmaceuticals Laboratories
Primary outcomeArea under the concentration-time curve within a dosing interval at Steady-State (SS AUCtau)
Hormone Receptor Positive Early Breast Cancer
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
Advanced Breast Cancer
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Primary outcomePercentage of Participants With Dose-Limiting Toxicities (DLTs)
Breast Cancer
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
SponsorMemorial Sloan Kettering Cancer Center
Primary outcomePhase II Dose of BYL719/Alpelisib (Arm A and Arm B)
Metastatic or Locally-advanced Unresectable Breast Cancer
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
SponsorMylan Pharmaceuticals Inc
Primary outcomeThe 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
Healthy
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
SponsorMridula George, MD
Primary outcomeSafety and tolerability of the combination of abemaciclib and radiation as assessed by adverse events (AEs). Using Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Breast Cancer
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
SponsorKyowa Kirin Co., Ltd.
Primary outcomeTo establish the safety, tolerability, and recommended Phase 2 dose of KW-2450 administered in combination with lapatinib and letrozole in subjects with previously treated or untreated advanced breast cancer.
Breast Cancer
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
SponsorGenor Biopharma Co., Ltd.
Advanced Breast Cancer
Ovulation Induction in Clomiphene Citrate Resistant PCO Women
Primary outcomeovulation rate
Polycystic Ovary SyndromeInfertility
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
SponsorSOLTI Breast Cancer Research Group
Primary outcomeChanges in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by PAM50
Breast Cancer
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary outcomeMean percentage change in Ki-67
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast CarcinomaHormone Receptor-Positive Breast CarcinomaInvasive Breast Carcinoma
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
SponsorVanderbilt-Ingram Cancer Center
Primary outcomePatients who complete the dietary intervention
Estrogen Receptor-positive Breast Cancer
IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC
SponsorHaukeland University Hospital
Primary outcomeChanges in the expression of biomarkers
Ovarian Cancer
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
SponsorOncolytics Biotech
Primary outcomeTo evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.
Breast Cancer
Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon
SponsorWashington State University
Primary outcomeNicotine area under the concentration vs. time curve (AUC) ratio (exposure/baseline)
Interaction Drug Food